DaVita To Pay Record $495M To Settle Kidney Drug FCA Suit

Law360, Los Angeles (May 4, 2015, 10:01 PM EDT) -- DaVita Inc. said Monday it set aside $495 million as part of a tentative deal to resolve a False Claims Act whistleblower suit for allegedly bilking taxpayers for reimbursement of intentionally overused dialysis drugs, which a plaintiff's attorney called the largest settlement for an FCA case brought without government intervention.

Whistleblowers claim DaVita Inc. and a subsidiary engaged in various schemes from 2003-10 designed to create unnecessary waste in the process of administering certain medications to generate higher reimbursements from the government and private insurers. (Credit:...
To view the full article, register now.